Novel Gb3 isoforms detected in urine of fabry disease patients: A metabolomic study

Current Medicinal Chemistry

Volumn 19, Issue 19, 2012, Pages 3241-3252

  Auray Blais, C ^a   Boutin, M ^a  

^a UNIVERSITY OF SHERBROOKE   (Canada)

Author keywords

Biomarkers; Fabry disease; Globotriaosylceramide (Gb3); Globotriaosylsphingosine (lyso Gb3); Lysosomal storage disorders; Metabolomics; Multivariate data analysis; Qtof mass spectrometry; Urine

Indexed keywords

BIOLOGICAL MARKER; GLOBOTRIAOSYLCERAMIDE; GLOBOTRIAOSYLSPHINGOSINE; SATURATED FATTY ACID; SPHINGOSINE; SPHINGOSINE DERIVATIVE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CHEMICAL ANALYSIS; CHEMICAL BOND; CHEMICAL INTERACTION; CHILD; CONTROLLED STUDY; DEACYLATION; EVALUATION; FABRY DISEASE; HUMAN; INFANT; MALE; METABOLITE; METABOLOMICS; METHYLATION; MOLECULAR DYNAMICS; MOLECULE; PATHOGENESIS; PRESCHOOL CHILD; SCHOOL CHILD; TIME OF FLIGHT MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; URINALYSIS; URINE;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; FABRY DISEASE; HUMANS; MALE; METABOLOMICS; MIDDLE AGED; PROTEIN ISOFORMS; YOUNG ADULT;

EID: 84863641265     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712800784739     Document Type: Article

References (31)

1. Clarke, J.T.R. Narrative review: Fabry disease. Ann. Intern. Med., 2007, 146, 425-433.
2. Mills, K.; Morris, P.; Lee, P.; Vellodi, A.; Waldek, S.; Young, E.; Winchester, B. Measurement of urinary CDH and CTH by tandem mass spectrometry in patients hemizygous and heterozygous for Fabry disease. J. Inherit. Metab. Dis., 2005, 28, 35-48.
3. Auray-Blais, C.; Cyr, D.; Ntwari, A.; West, M.L.; Cox-Brinkman, J.; Bichet, D.G.; Germain, D.P.; Laframboise, R.; Melançon, S.B.; Stockley, T.; Clarke, J.T.R.; Drouin, R.; Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease. Mol. Genet. Metab., 2008, 93, 331-340.
4. Aerts, J.M.; Groener, J.E.; Kuiper, S. Donker-Koopman, W.E.; Strijland, A.; Ottenhoff, R.; van Roomen, C.; Mirzaian, M.; Wijburg, FA.; Linthorst, G.E.; Vedder, A.C.; Rombach, S.M.; Cox-Brinkman, J.; Somerharju, P.; Boot, R.G; Hollak, C.E.; Brady, R.O.; Poorthuis, B.J. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc. Natl. Acad. Sci., 2008, 105, 2812-2817.
5. 3 function as a biomarker in Fabry disease? Clin. Chim. Acta., 2010, 411, 1906-1914.
6. Auray-Blais, C.; Millington, D.; Young, S.P.; Clarke, J.T.R.; Schiffmann, R. Proposed high-risk screening protocol for Fabry disease in patients with renal and vascular disease. J Inherit Metab Dis., 2009, 32(2), 303-308.
7. Auray-Blais, C.; Cyr, D.; Mills, K.; Giguère, R.; Drouin, R. Development of a filter paper method potentially applicable to mass and high-risk urinary screenings for Fabry disease. J. Inherit. Metab. Dis., 2007, 30(1), 106.
8. Meikle, P.J.; Hopwood, J.J.; Clague, AE.; Carey, W.F. Prevalence of lysosomal storage disorders. J.A.M.A., 1999, 281, 249-254.
9. Spada, M.; Pagliardini, S.; Yasuda, M.; Tukel, T.; Thiagarajan, G.; Sakuraba, H.; Ponzone, A.; Desnick, R.J. High incidence of later-onset Fabry disease revealed by newborn screening. Am. J. Hum. Genet., 2006, 79, 31-40.
10. Schiffmann, R.; Askari, H.; Timmons, M.; Robinson, C.; Benko, W.; Brady, R.O.; Ries, M. Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing. J. Am. Soc. Nephrol., 2007, 18(5), 1576-1583.
11. Wraith, JE.; Tylki-Szymanska, A.; Guffon, N.; Lien, Y.H.; Tsimaratos, M.; Vellodi, A.; Germain, D.P. Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease. J. Pediatr., 2008, 152(4), 563-570.
12. Hughes, D.A.; Elliott, P.M.; Shah, J.; Zuckerman, J.; Coghlan, G.; Brookes, J.; Mehta, A.B. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart., 2008, 94(2), 153-158.
13. Cox, T.M. Biomarkers in lysosomal storage diseases, In: Fabry Disease: Perspectives from 5 Years of FOS; Mehta A, Beck M, Sunder-Plassmann G, Ed.; Oxford: Oxford PharmaGenesis; 2006.
14. Biancini, G.B.; Vanzin, C.S.; Rodrigues, D.B.; Deon, M.; Ribas, G.S.; Barschak, A.G.; Manfredini, V.; Netto, C.B.; Jardim, L.B.; Giugliani, R.; Vargas, C.R. Globotriaosylceramide is correlated with oxidative stress and inflammation in Fabry patients treated with enzyme replacement therapy. Biochim. Biophys. Acta., 2012, 1822(2), 226-232.
15. Deegan, P.B. Fabry disease, enzyme replacement therapy and the significance of antibody responses. J. Inherit. Metab. Dis., 2012, 35(2), 227-243.
16. Schiffmann, R.; Warnock, D.G.; Banikazemi, M.; et al. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol. Dial. Transplant., 2009, 24, 2102-2111.
17. West, M.L.; Nicholls, K.; Mehta, A.; Clarke, J.T.R.; Steiner, R.; Beck, M.; Barshop, B.A.; Rhead, W.; Mensah, R.; Ries, M.; Schiffmann, R.; Agalsidase alfa and kidney dysfunction in Fabry disease. J. Am. Soc. Nephrol., 2009, 20, 1132-1139.
18. Schiffmann, R.; Waldek, S.; Benigni, A.; Auray-Blais, C. Biomarkers of Fabry disease nephropathy. Clin. J. Am. Soc. Nephrol., 2010, 5, 360-364.
19. 3 analogs as Fabry disease biomarkers. Curr. Med. Chem., 2012 (In revision).
20. 3-related biomarkers for Fabry Disease targeted by metabolomics. Anal. Chem., 2012, 20;84(6), 2745-2753.
21. Sullards, M.C.; Liu, Y.; Chen, Y.; Merrill, A.H. Jr. Analysis of mammalian sphingolipids by liquid chromatography tandem mass spectrometry (LC-MS/MS) and tissue imaging mass spectrometry (TIMS). Biochim. Biophys. Acta., 2011, 1811(11):838-853.
22. Fauler, G.; Rechberger, G.N.; Devrnja, D.; Erwa, W.; Plecko, B.; Kotanko, P.; Breunig, F.; Paschke, E. Rapid determination of urinary globotriaosylceramide isoform profiles by electrospray ionization mass spectrometry using stearoyl-d35-globotriaosylceramide as internal standard. Rapid. Commun. Mass. Spectrom., 2005, 19(11), 1499-1506.
23. Young, E.; Mills, K.; Morris, P.; Vellodi, A.; Lee, P.; Waldek, S.; Winchester, B. Is globotriaosylceramide a useful biomarker in Fabry disease? Acta. Paediatr. Suppl., 2005, 94(447), 51-54.
24. Kitagawa, T.; Ishige, N.; Suzuki, K.; Owada, M.; Ohashi, T.; Kobayashi, M.; Eto, Y.; Tanaka, A.; Mills, K.; Winchester, B.; Keutzer, J. Non-invasive screening method for Fabry disease by measuring globotriaosylceramide in whole urine samples using tandem mass spectrometry. Mol. Genet. Metab., 2005, 85, 196-202.
25. Lohse, B.; Kristensen, J.L.; Kristensen, L.H.; Agger, K.; Helin, K.; Gajhede, M.; Clausen, R.P. Inhibitors of histone demethylases. Bioorg. Med. Chem., 2011, 19(12), 3625-3636.
26. Dhall, A.; Chatterjee, C. Chemical approaches to understand the language of histone modifications. ACS Chem. Biol., 2011, 6, 987-999.
27. Bai, H.W.; Shim, J.Y.; Zhu, B.T. Biochemical and molecular modeling studies of the O-methylation of various endogenous and exogenous catechol substrates catalyzed by recombinant human soluble and membrane-bound catechol-O-methyltranferases. Chem. Res. Toxicol., 2007, 20(10), 1409-1425.
28. Finkelstein, J.D. Metabolic regulatory properties of S-adenosylmethionine and S-adenosylhomocysteine. Clin. Chem. Lab. Med., 2007, 45(12), 1694-1699.
29. van Breemen, M.J.; Rombach, S.M.; Dekker, N.; Poorthuis, B.J.; Linthorst, G.E.; Zwinderman, A.H.; Breunig, F.; Wanner, C.; Aerts, J.M.; Hollak, C.E. Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy. Biochim. Biophys. Acta., 2011, 1812(1), 70-76.
30. Rombach, S.M.; Dekker, N.; Bouwman, M.G.; Linthorst, G.E.; Zwinderman, A.H.; Wijburg, F.A.; Kuiper, S.; Vd, Bergh,; Weerman, M.A.; Groener, J.E.; Poorthuis, B.J.; Hollak, C.E.; Aerts, J.M. Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease. Biochim. Biophys. Acta., 2010, 1802(9), 741-748.
31. Togawa, T.; Kodama, T.; Suzuki, T.; Sugawara, K.; Tsukimura, T.; Ohashi, T.; Ishige, N.; Suzuki, K.; Kitagawa, T.; Sakuraba, H. Plasma globotriaosylsphingosine as a biomarker of Fabry disease. Mol. Genet. Metab., 2010, 100(3), 257-261.